Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with erdafitinib may alter the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, resulting in increased toxicity or decreased efficacy of these drugs. In vitro, erdafitinib has been shown to be a time-dependent inhibitor as well as inducer of CYP450 3A4. However, no pharmacokinetic data are available from drug interaction studies.

MANAGEMENT: Concomitant use of erdafitinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.

Grapefruit, pomelo, and juices or supplements containing these fruits may increase the blood levels of palovarotene, which may increase the risk and/or severity of side effects such as dry skin, dry lips, hair loss, skin rash, itching, skin and nail infection, dry eyes, night blindness, depression, and mood changes. It may also increase the risk of a rare, but potentially serious, condition called pseudotumor cerebri caused by increased pressure in the brain. Palovarotene should be taken with food at approximately the same time each day. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.